Free Trial
→ Gold to $27,533? (From Stansberry Research) (Ad)tc pixel
Michael Schmitz

Michael Schmitz Analyst Performance

Senior Managing Director & Equity Research Analyst at Guggenheim

Michael Schmitz is a stock analyst at Guggenheim focused in the energy sector, covering 9 publicly traded companies. Over the past year, Michael Schmitz has issued 3 stock ratings, including buy and hold recommendations. While full access to Michael Schmitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Schmitz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 8 Years
Buy Recommendations
80.00% 8 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy80.0%8 ratings
Hold20.0%2 ratings
Sell0.0%0 ratings

Out of 10 total stock ratings issued by Michael Schmitz at Guggenheim, the majority (80.0%) have been Buy recommendations, followed by 20.0% Hold.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NYSE
66.7% of companies on NYSE
6 companies
NASDAQ
33.3% of companies on NASDAQ
3 companies

Michael Schmitz, an analyst at Guggenheim, currently covers 9 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Energy
7 companies		77.8%
Medical
2 companies		22.2%

Michael Schmitz of Guggenheim specializes in stock coverage within the Energy sector, with additional focus on Medical companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies		22.2%
OIL - US EXP&PROD
2 companies		22.2%
CRUDE PETROLEUM & NATURAL GAS
2 companies		22.2%
PIPELINES, EXCEPT NATURAL GAS
1 company		11.1%
DRILLING OIL & GAS WELLS
1 company		11.1%
OIL - US INTEGRTD
1 company		11.1%

About Michael Schmitz

Dr. Schmidt is a Senior Managing Director and Equity Research Analyst covering the Biotechnology sector based in Guggenheim’s Boston office. With over 17 years of Wall Street experience, Dr. Schmidt joined Guggenheim from Leerink Partners in 2018 where he was a Senior Biotechnology Research Analyst. Previously, he was a healthcare analyst and consultant at Susquehanna International Group’s private equity team in San Francisco and a research fellow at Harvard University. Dr. Schmidt earned his M.S. in Biology and Ph.D. in Biochemistry at the University of Stuttgart, Germany. Dr. Schmidt was named runner-up in the 2017 Institutional Investor All-America Research Survey, Biotechnology/Mid- & Small-Cap.
Follow on LinkedIn

Michael Schmitz's Ratings History at Guggenheim

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Merus N.V. stock logo
MRUS
Merus
9/30/2025Reiterated Rating$93.61$97.00Neutral
Merus N.V. stock logo
MRUS
Merus
9/29/2025Downgrade$94.15Hold
Exelixis, Inc. stock logo
EXEL
Exelixis
7/29/2025Reiterated Rating$37.59$45.00Buy
Today's Ratings
Top-Rated Stocks
More Ratings Tools